NCT00849667 2022-12-30Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First RelapseMorphotekPhase 3 Terminated1,100 enrolled 30 charts
NCT01018563 2021-12-08An Open Label Extension Study of the Efficacy of MORAb-003MorphotekPhase 2 Terminated3 enrolled 12 charts